Masonic Cancer Center

A comprehensive cancer center designated by the National Cancer Institute


Master regulator of key cancer gene found, offers new drug target

Research conducted by the laboratory of Anindya Bagchi, Ph.D., Genetic Mechanisms of Center Program, was highlighted in Medical Xpress and HealthCanal stories. Bagchi and his colleagues discovered how MYC, a gene linked to cancer, is regulated by a non-coding RNA, PVT1. The research was recently published in the journal Nature.

Tribute to a leader

AHCMCC2 - Image - Kersey family - 200X112

A permanent tribute to the Masonic Cancer Center's founder, John Kersey, M.D. was unveiled in a ceremony Tuesday, May 13 in the new Cancer Cardiovascular Research Building in the Biomedical Discovery District of the University of Minnesota.  Dr. Kersey's family was on hand to join in t

he celebration of his life and contributions to cancer research and treatment. A story on the event appeared in the Star Tribune. Learn more about the display.

2013 Research Update published

The Masonic Cancer Center has published Research Update 2013: A Tribute to Dr. John Kersey's Legacy. View the pdf.

NCI renews Masonic Cancer Center as Comprehensive Cancer Center

The National Cancer Institute has renewed its designation of the Masonic Cancer Center, University of Minnesota, as a comprehensive cancer center after a highly competitive and rigorous process. The reviewers recommended support for the Masonic Cancer Center of nearly $20M over the next 5 years. Read more.

AHCMCC2 - Photo 200x112_Ambulatory Care CtrNew Ambulatory Care Center will provide transformative team-based patient care 

The University of Minnesota and Fairview Health Services recently broke ground on a new, state-of-the-art Ambulatory Care Center, which will house outpatient clinics currently located in the Phillips-Wangensteen Building, the Masonic Cancer Clinic and an outpatient surgery center. Read more 

U of M researchers investigating exposures caused by e-cigarettes

Investigations are underway at the Masonic Cancer Center, University of Minnesota, to determine the level of nicotine and toxin exposures caused by the use of e-cigarettes, a category of products with no established baseline. The study is recruiting e-cigarette users, both who use the products exclusively and those who also use cigarettes. Read more.

Natalie Wolf, sarcoma survivor and U of M student, conducts sarcoma research in the Masonic Cancer Center

The November issue of Rein in Sarcoma newsletter featured Natalie Wolf, a University of Minnesota student and sarcoma survivor, who is working in the laboratory of David Largaespada, Ph.D., Genetic Mechanisms of Cancer Program. Read more.

Varsity Team Rally III raises more than $100,000 for Masonic Cancer Center research 

On September 18, the Cancer and Cardiovascular Research Building was the site of Varsity Team Rally III, a one-evening event that raised more than $100,000 for the Genomic Signatures for Colorectal Cancer project at Masonic Cancer Center. Emceed by U of M Athletic Director Norwood Teague, the event brought together community supporters and donors to hear from cancer researchers and tour the new facility. President Eric 

Kaler and Masonic Cancer Center Director Douglas Yee, M.D., were also part of the program. Read more.

Hyundai Hope on Wheels awards grant to Masonic Cancer Center researcher

AHCMCC2 - Spector 340-190 - ImageLogan Spector, Ph.D., is the recipient of a two-year $250,000 grant from Hyundai Hope on Wheels to study the genetic causes of osteosarcoma in children. The grant will be used to examine the protein-coding portions of the genomes (known as exomes) of about 100 osteosarcoma patients and their parents. By comparing patients' exomes to their parents' new mutations will be located. Genes where these mutations cluster will be considered very likely to be involved in causing osteosarcoma. Knowing the genetic causes of osteosarcoma may suggest new therapies and screening strategies to catch tumors earlier and improve patient outcomes.

New breast cancer drug combats early-stage breast cancer

Douglas Yee, M.D., Masonic Cancer Center director and a University of Minnesota Physicians breast cancer specialist, appeared on Fox 8 last week to discuss a new drug that combats breast cancer in its earliest stages. Read more.

  • ©2014 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on April 9, 2014